China Biologic Now Included in the NASDAQ Global Select Market

TAI'AN, China, Jan. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that NASDAQ has notified it that the Company has met the initial listing requirements for the NASDAQ Global Select Market. Therefore, beginning January 3, 2011, China Biologic is now included in the NASDAQ Global Select Market.

Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic, said, "I believe that being included in the NASDAQ Global Select Market is a good indicator that we are on the right road to achieving our long-term operating and financial goals for the Company, which include creating value for shareholders. We are both very pleased and honored to be included in NASDAQ's highest market tier."

NASDAQ Global Select Market: The world's highest standards

According to NASDAQ, the NASDAQ Global Select Market(SM) is for public companies that meet the highest listing standards in the world, with measures including market value, liquidity, and earnings. Inclusion in the NASDAQ Global Select Market is a mark of achievement and stature for qualified companies. Listing on NASDAQ represents companies' commitment to provide investors with superior market quality. Investors benefit not only from lower trading costs on NASDAQ but also by knowing that NASDAQ Global Select Market companies are models of leadership and have met the highest standards of any market in the world. Companies qualifying for the NASDAQ Global Select Market make up approximately one-third of NASDAQ listings and reflect the diversity of NASDAQ as a whole, in terms of market cap and across industry sectors, according to NASDAQ.

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd., and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website at http://www.chinabiologic.com.